Average time Control-IQ participants spent in closed-loop over a six-month period.1
Percent of Control-IQ participants said the feature on the t:slim X2 insulin pump was easy to use.2
Average time in range per day spent by Control-IQ participants, versus 59% with sensor augmented pump.1
In a 6-month, National Institutes of Health-funded trial, study participants completed a technology acceptance survey, and using a 5‑point scale, rated Control-IQ™ technology on the t:slim X2™ insulin pump a 4.8 for desire to continue using the system, 4.7 for ease of use, 4.6 for usefulness, and 4.5 for trust.2See the evidence
The t:slim X2 insulin pump can be used with or without continuous glucose monitoring (CGM).‡ For your patients who do use CGM, you can also prescribe either Control-IQ or Basal-IQ® technology for automated insulin delivery.
Like all Tandem products, Control-IQ technology is easy to use, learn, and teach. Our predictive technologies integrate with your patients’ existing t:slim X2 insulin pump, so they don’t need to learn an entirely new system.
Through the t:connect® HCP web application, you can upload, view, and print patient data from a single user-friendly webpage accessible from any internet-connected computer, anytime, anywhere in the United States.
The t:slim X2 insulin pump integrates with the Dexcom G6 CGM and does not require fingersticks for calibration or mealtime dosing.†
† If glucose alerts and Dexcom G6 CGM readings do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
Review clinical study outcomes, compare product specs, and check out the reporting capabilities of t:connect HCP web application.
Find all the information you need to make prescribing easy for your practice, and to help get your patients started on Tandem products.
* If glucose values are predicted to be above 180 mg/dL, Control-IQ technology calculates a correction bolus using the Personal Profile settings and a target of 110 mg/dL and delivers 60% of that value. It will do this up to once per hour as needed.
† Zero fingersticks required when using the t:slim X2 pump with Dexcom G6 CGM integration. If glucose alerts and CGM readings do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
‡ CGM sold separately.
§ As measured by CGM
1. Brown SA, Kovatchev BP, Raghinaru D, et al. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. N Engl J Med. 2019;381(18):1707-17. DOI: 10.1056/NEJMoa1907863
2. Brown S, et al. Clinical Acceptance of the Artificial Pancreas: The iDCL Trial. Poster presentation. 79th Scientific Sessions, American Diabetes Association, San Francisco, CA; June 9, 2019.
Important Safety Information
RX ONLY. The t:slim X2 insulin pump, Basal-IQ technology, and Control-IQ technology are intended for single patient use. The t:slim X2 pump, Basal-IQ technology, and Control-IQ technology are indicated for use with NovoLog or Humalog U-100 insulin.
t:slim X2 insulin pump: The t:slim X2 insulin pump with interoperable technology is an alternate controller enabled (ACE) pump that is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in individuals six years of age and greater. Basal-IQ technology:Basal-IQ technology is intended for use with a compatible integrated continuous glucose monitor (iCGM, sold separately) and ACE pump to automatically suspend delivery of insulin based on iCGM readings and predicted glucose values. The bolus calculator is indicated for the management of diabetes by people with diabetes by calculating an insulin dose or carbohydrate intake based on user entered data. Basal-IQ technology is intended for the management of diabetes mellitus in persons six years of age and greater. Control-IQ technology:Control-IQ technology is intended for use with a compatible iCGM (sold separately) and ACE pump to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ technology is intended for the management of Type 1 diabetes mellitus in persons six years of age and greater.
|WARNING: Control-IQ technology should not be used by anyone under the age of six years old. It should also not be used in patients who require less than 10 units of insulin per day or who weigh less than 55 pounds.|
Control-IQ technology and Basal-IQ technology are not indicated for use in pregnant women, people on dialysis, or critically ill patients. Do not use Control-IQ technology if using hydroxyurea. Users of the t:slim X2 pump, Basal-IQ technology, and Control-IQ technology must: be able and willing to use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders. The t:slim X2 pump, transmitter, and sensor must be removed before MRI, CT, or diathermy treatment. visit www.tandemdiabetes.com/safetyinfo for additional important safety information.